OBT076

OBT076 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonal antibody targeting the CD205 (also known as DEC205 or Ly75) receptor, which is overexpressed on the surface of various solid and liquid tumor cells as well as immunosuppressive dendritic cells. The antibody is conjugated via a cleavable linker to DM4 (ravtansine), a potent maytansinoid microtubule inhibitor. OBT076 selectively binds to CD205-positive cancer cells, delivering the cytotoxic payload directly into these cells, leading to their death while minimizing damage to healthy tissue. Additionally, OBT076 may deplete immunosuppressive CD205+ cells in the tumor microenvironment and promote immune system reactivation against tumors—a potential dual mechanism of action. It is being developed primarily for advanced or refractory solid tumors with high CD205 expression, including gastric cancer, non-small cell lung cancer, endometrial cancer, ovarian cancer, breast cancers (including triple-negative), bladder cancer, pancreatic cancers and certain lymphomas such as diffuse large B-cell lymphoma[1][2][3][4][5][6][7][8].

Other names

CD205-ADCCD-205-ADCCD 205-ADC